MyelinWatch EL
← Back to updates
Myelin repairLaboratory cells onlyLaboratory model of myelin repair; no clinical outcome

Peer-reviewed laboratory model using human stem-cell-derived tissue; no patients treated

Human cell spheroids model myelin injury and repair in the laboratory

Published by MyelinWatch:

Organisation
Ramesan et al. research team

What happened

A Nature Neuroscience paper published on 1 October 2026 describes three-dimensional spheroids made from human induced pluripotent stem cells. They contain myelinating oligodendrocytes and responsive microglia. After experimentally induced myelin injury, researchers observed debris clearance, generation of new oligodendrocytes and new, thinner myelin sheaths around axons. Remyelination was observed in only about half of differentiations. Developmental maturity is another limitation: stem-cell-derived models may not fully reflect adult tissue. The model can help study repair mechanisms and screen candidate compounds, but a spheroid cannot reproduce all features of adult multiple sclerosis (MS).

What this means for people with MS

This is laboratory research, not a clinical trial or a treatment. No person with MS received an intervention in this study, and the paper does not demonstrate restored myelin or improved disability in patients. Any drug lead from this model would need separate testing. It establishes no treatment access in Greece.

About the approach studied in this programme: Human iPSC myelin spheroid model

Scientists grow three-dimensional spheres from human stem cells with myelin-making oligodendrocytes and microglia, then deliberately injure their myelin. The model lets them observe debris clearance and formation of new sheaths in a dish; it is a laboratory research tool, not a cell treatment given to people with MS.

Approach source: Nature Neuroscience — original spheroid-model article ↗

What kind of evidence exists?
Original peer-reviewed Nature Neuroscience cell-model study
How reliable is this source?
Original peer-reviewed Nature Neuroscience paper, DOI 10.1038/s41593-026-02457-z, PMID 42823475

Related study or programme: Human iPSC myelin spheroid model →

Source: Nature Neuroscience — Ramesan et al. — original peer-reviewed research article ↗Source: PubMed — Nature Neuroscience original article PMID 42823475 ↗
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Research event/source date:
Myelin repairResults from peopleNo reported conclusion on effect

Published longitudinal imaging cohort study in people

MRI study follows a myelin-sensitive signal in MS lesions over about one year

Organisation: Second Hospital & Clinical Medical School, Lanzhou University · China

Researchers at the Second Hospital of Lanzhou University, China, used an MRI technique called APART-QSM, which separates a myelin-sensitive (diamagnetic) signal from an iron-sensitive one. At the first scan, white matter lesions had a lower myelin-sensitive signal than the corresponding normal-appearing white matter. In the 101 people with multiple sclerosis who had a second scan after a median of about one year, the myelin-sensitive signal in lesions increased. Larger increases were associated with female sex, ofatumumab treatment, relapsing-remitting MS and improvement in EDSS disability scores, and they were smaller with longer disease duration.

Published by MyelinWatch:

What this means for people with MS

The work tests whether this MRI method could track changes linked to remyelination. It does not show that myelin was restored, that ofatumumab repairs myelin, or that the signal explains changes in disability: this was an observational cohort with no randomised comparison of treatments, and about 30% of the people with MS had no follow-up scan. There is still no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: Journal of Magnetic Resonance Imaging (Wiley) — peer-reviewed primary article ↗
Research event/source date:
Myelin repairLaboratory or animal researchLess myelin damage and inflammation in mouse models; not clinical benefit

Mouse experiments; not tested in people

Mouse study links chronic demyelination to a dysfunctional microglial state

Organisation: Technical University of Munich and German Center for Neurodegenerative Diseases (DZNE) · Germany

Researchers at the Technical University of Munich and the German Center for Neurodegenerative Diseases (DZNE) compared mouse models of acute and chronic myelin loss. With chronic demyelination, microglia, the brain's immune cells, entered a distinct state with ongoing inflammation, fats trapped inside their lysosomes and fewer lipid droplets, together with higher cholesterol production and lower cholesterol export. A desmosterol-like compound (DMHCA) reversed this state, reduced inflammatory signalling and myelin damage, and improved movement in a mouse model of the inherited myelin disorder Pelizaeus–Merzbacher disease. In experimental autoimmune encephalomyelitis (EAE), a mouse model used to study MS, DMHCA lessened disease severity and reduced lesions. In post-mortem tissue from chronic active MS lesions of 3 people, about 75% of phagocytic immune cells (CD68+) carried a marker of this inflammatory state (CCL4), compared with about 13% in white matter from people without MS.

Published by MyelinWatch:

What this means for people with MS

The study points to a possible research target for chronic myelin damage, including in MS. The compound was given only to mice, EAE mice do not reproduce all features of MS, and the human finding is a small descriptive tissue observation, so the work cannot show that the compound would be safe or useful for people with multiple sclerosis. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: Nature Neuroscience — peer-reviewed primary article ↗
Research event/source date:
Myelin repairLaboratory or animal researchMore maturing myelin-forming cells in aged rodents; not clinical benefit

Rat cell and mouse experiments; not tested in people

Rodent study: restoring BCL11A helped aged myelin precursor cells mature

Organisation: Altos Labs-Cambridge Institute of Science and University of Cambridge · United Kingdom

Researchers at Altos Labs-Cambridge Institute of Science and the University of Cambridge, UK, studied why oligodendrocyte progenitor cells, the precursor cells that can form new myelin, mature less well with age. Using a new computational method (gSWITCH) on gene-activity data from young and aged rats, they found several regulatory genes with lower activity in aged precursor cells and highlighted one, BCL11A. Blocking BCL11A reduced the maturation of these precursor cells into myelin-forming cells (oligodendrocytes). Adding BCL11A to precursor cells from aged rats in the lab increased the number of oligodendrocytes by about 54% without changing cell division. In 18-month-old mice, raising BCL11A in these cells with a viral gene vector before a chemically induced spinal cord lesion led to more maturing oligodendrocytes in the lesion 14 days later; the authors report no difference in lesion size.

Published by MyelinWatch:

What this means for people with MS

The study points to a gene that may help explain why myelin repair slows with age, a question relevant to MS. It did not test a treatment: BCL11A was raised by gene delivery in rodents, the lesion was chemically induced rather than an MS model, and the study counted maturing cells rather than measuring restored myelin or recovery of function. It cannot show that this approach would be safe or useful for people with multiple sclerosis. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: eLife — peer-reviewed primary article ↗